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Abstract 
The spike protein of SARS-CoV-2 has become the main target for antiviral and 
vaccine development. Despite its relevance, there is scarce information about its 
evolutionary traces. The aim of this study was to investigate the diversification 
patterns of the spike for each clade of SARS-CoV-2 through different approaches.  
 
 











Two thousand and one hundred sequences representing the seven clades of the 
SARS-CoV-2 were included. Patterns of genetic diversifications and nucleotide 
evolutionary rate were estimated for the spike genomic region. 
The haplotype networks showed a star shape, where multiple haplotypes with few 
nucleotide differences diverge from a common ancestor. Four hundred seventy nine 
different haplotypes were defined in the seven analyzed clades. The main haplotype, 
named Hap-1, was the most frequent for clades G (54%), GH (54%), and GR (56%) 
and a different haplotype (named Hap-252) was the most important for clades L 
(63.3%), O (39.7%), S (51.7%), and V (70%). The evolutionary rate for the spike 
protein was estimated as 1.08 x 10-3 nucleotide substitutions/site/year. Moreover, the 
nucleotide evolutionary rate after nine months of pandemic was similar for each 
clade. 
In conclusion, the present evolutionary analysis is relevant since the spike protein of 
SARS-CoV-2 is the target for most therapeutic candidates; besides, changes in this 
protein could have consequences on viral transmission, response to antivirals and 
efficacy of vaccines. Moreover, the evolutionary characterization of clades improves 
knowledge of SARS-CoV-2 and deserves to be assessed in more detail since re-
infection by different phylogenetic clades has been reported. 
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Introduction  
In December 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) emerged and shocked the entire world [1]. After a year of worldwide 
circulation, more than 98 million cases and 2 million deaths have been reported 
globally [2]. Seven genetic clades (S, L, O, V, G, GR, and GH) have been described 
over time that are spread throughout different countries [3]. These clades represent a 
challenge for public health as re-infection cases with different clade strains have 
been reported [4,5,6]. In fact, more than 200 candidates for vaccines against SARS-
CoV-2 and several antivirals are already being developed [7,8]. Most of vaccines and 
therapeutic drugs are directed towards the spike glycoprotein (S) that is responsible 
for entering the host cell through recognition of the receptor ACE2 with the receptor 
binding protein (RBD) [8,9,10,11,12]. Therefore, knowing the evolutionary rate of the S is 
relevant since changes in this protein could affect the efficacy of the vaccine and the 
antivirals directed to S. Even though some studies have determined the nucleotide 
evolutionary rate of SARS-CoV-2 using the entire genome [13,14], those values are 
 
 











slower and do not represent the real mutation capacity of the S region alone. Only 
one study has reported the nucleotide evolutionary rate of the S genomic region in 
the first four months of the pandemic, but without differentiating the seven viral 
clades, which can be relevant in therapeutics and re-infections [15]. Thus, the aim of 
this study was to determine the nucleotide evolutionary rate and the haplotype 
network of the S region for SARS-CoV-2 in general and for each of the seven genetic 
clades during the first nine months of pandemic. 
Materials and Methods 
Datasets 
In order to generate datasets representing different geographic regions and time 
evolution for each of the seven clades of SARS-CoV-2, from December 2019 to 
September 2020, data of complete genome sequences available at GISAID (https: 
//www.gisaid.org /) on September 2020 were randomly monthly collected for several 
geographic regions. Data inclusion criteria were: a.- complete genomes, b.- high 
coverage level, and c.- human host only (no other animals or environmental 
samples). Complete genomes were aligned using MAFFT against the Wuhan-Hu-1 
reference genome (NC_045512.2, EPI_ISL_402125). The resulting multiple 
sequence alignments were split in a dataset corresponding to the S region [3,822nt 
(21,563-25,384)] and RBD (included in S) [762nt (22,550-23,311)].  
Phylogenetic and statically analysis / Genetic characterization 
Patterns of genetic diversifications for both genomic regions S and RBD for each 
clade were analyzed using the median-joining reconstruction method at the PopART 
v1.7.2 software [16]. Haplotypes shared among all clades were analyzed in Arlequin 
3.5.2.2 software [17]. Polymorphism indices were calculated separately for each clade 
with DnaSPv. 6.12.01 [18].  
Nucleotide evolutionary rate 
The estimation of the nucleotide evolutionary rate for the entire S-coding region 
datasets were carried out with the Beast v1.8.4 program package [19] at the CIPRES 
Science Gateway server [20]. The temporal calibration was established by the 
samples’ date of sampling. The best nucleotide substitution model was selected 
according to the Bayesian information criterion (BIC) method in IQ-TREE v1.6.12 
software [21]. The analysis was performed under a relaxed (uncorrelated lognormal) 
molecular clock model recommended previously by Duchene & col. [22] with an 
exponential demographic model [23]. Analyses were run for 8x106 generations and 
sampled every 8x105 steps. The convergence of the "meanRate" and “allMus” 
parameters [effective sample size (ESS) ≥ 200, burn-in 10%] was verified with Tracer 
v1.7.1 [24]. The obtained substitution rate was probed against 10 independent 
 
 











replicates of the analysis with the time calibration information (date of sampling) 
randomized as described by Rieux & Khatchikian, 2017 [25].  
Results 
Datasets 
Three-hundred sequences were randomly selected for each clade. Two thousand 
and one hundred sequences were curated and selected for the analysis. Table 1 
shows the SARS-CoV-2 sequences included for every month and clade.  
Phylogenetic and statically analysis / Genetic characterization 
The haplotype networks (Figure 1) reflect the diversity indices results as a star shape 
with multiple haplotypes with few nucleotide differences that diverge from a common 
ancestor. In all cases, the RBD diversification is lower than the spike one, being the 
lowest for clades S and V. For the S-coding region, 479 different haplotypes were 
defined in the seven analyzed clades. The number of haplotypes observed among 
clades ranged from 53 for the V clade to 89 for the GH and GR clades (Table 2). The 
major haplotype 1 (Hap-1), defined by amino acids S12, L18, R21, A222, N439, 
S477, T478, A522, E583, G614, Q675, E780, D936, V1068, and P1263 was the 
most frequent for clades G (54%), GH (54%), and GR (56%). However, other 10 
haplotypes with amino acid changes respect to the Hap-1 were also observed. On 
the other hand, haplotype 252 (Hap-252), defined by amino acids L5, L8, H49, V367, 
A575, D614, A829, A846, D1084, and A1087 was the most frequent for clades L 
(63.3%), O (39.7%), S (51.7%), and V (70%). In addition, other 10 haplotypes 
showed one amino acid change respect to Hap-252. Table 3 shows the frequency of 
each haplotype with amino acid changes.  
The haplotype diversity was moderate to high in every clade, ranging from Hd = 0.507 
to 0.793 (Table 2). In contrast, nucleotide diversity was relatively low for each clade, 
ranging between π = 0.0018 for V and π = 0.0040 for O (Table 2). Although overall 
diversity was similar among different clades, haplotype and nucleotide diversities 
were both the lowest for V. On the other hand, haplotype and nucleotide diversity 
was higher for G, GH, GR, and O (Table 2). The RBD region showed indices with a 
similar trend but with lower values compared to the S region. 
Evolutionary rate 
After nine months of pandemic, the estimated evolutionary rate for the S genomic 
region of SARS-CoV-2 was 1.08 x 10-3 nucleotide substitutions per site per year 
(s/s/y) (95% HPD interval 7.94 x 10-4 to 1.41 x 10-3 s/s/y). Additionally, the nucleotide 
evolutionary rate for the different genetic clades ranged between 1.06 x 10-3 and 1.69 
x10-3 s/s/y (Table 4). A date-randomization analyses showed no overlapping between 
the 95% HPD substitution-rate intervals obtained from real data and from date-
randomized datasets for all clades (Figure 2).  
Dataset for the clade L did not reach convergence (ESS<200). To verify the reliability 
of the result, 10 independent runs were performed. All of them converged in a similar 
posterior distribution. Likewise, for many of the random sample datasets, 
convergence was not achieved (ESS between 100 and 200). For those datasets that 
 
 











did not reach convergence, two independent runs were carried out and concatenated 
[26].  
When the evolutionary rate was analyzed according to the emergence of each clade, 
founding clades (L, O, S, and V) tended to present evolutionary rates slightly slower 
than the more recent clades (G, GH, and GR), (p = 0.157).  
Discussion 
The evolutionary characterization of spike genomic region of SARS-CoV-2 is crucial 
to estimate the course that re-infections, vaccines, and therapeutics would have in 
the pandemic’s future. In this study, the evolutionary rate of the most important 
SARS-CoV-2 protein for vaccine development was estimated in general and 
separately for each genetic clade described in GISAID. In this context, the spike 
haplotype network showed a founding central paternal haplogroups from which 
multiple sequences with modest changes derived. Overall, the nucleotide 
evolutionary rate after nine months of pandemic was similar for each clade.  
At the beginning of the pandemic, the most prevalent clades were L, O, V, and S. 
Later, with the appearance of the D614G mutation in the S protein, clade G emerged 
and remained with a high and stable prevalence. After this initial step, the GR clade 
has emerged and grown until it became the most prevalent. Finally, the GH clade 
peaked at 30% in May 2020 and then began to decrease [3]. In this sense, it is 
important to highlight that clades with the mutation D614G in the S protein (clades G, 
GH, and GR) have been suggested to present a higher transmission efficiency 
although they would not be associated with a more severe pathogenesis [27]. 
Therefore, in order to describe the evolution of the S protein variants, the study of 
haplotypes network in all seven clades and for both regions (S and RBD alone) was 
performed. This analysis showed several identical sequences grouped together 
resulting in a star-shaped network, which is characteristic of viral outbreaks [28]. For 
the spike, this general analysis was supported by statistics that show a large number 
of haplotypes with a small number of nucleotide changes (low nucleotide diversity). 
However, for the RBD region, an increase in identical haplotypes was observed, 
which translates into a decrease in other parameters (H, Hd, and Π). This may be 
due to the conserved nature of the cell receptor-binding region, which is necessary 
for the infection of target cells. It is noteworthy that the lowest gene and nucleotide 
diversities observed for clade V, in both S and RBD, could be the result of fewer 
sequences available for this clade during the nine months analyzed here. In this way, 
it can be observed that more than 90% of the V clade sequences were distributed in 
four months (February to May). On the other hand, the highest nucleotide diversity 
observed in clade O is the result of a less clearly defined pattern of mutations [29]. 
Several amino acid changes detected in the haplotypes present in our analysis are 
part of the RBD (V367F, S477N, N439K, T478I, and A522S). From these amino acid 
changes, positions 367 and 439 were associated with the binding affinity of RBD 
[30,31]. Additionally, the mutation L5F in the signal peptide was present in 3.3% of 
members belonging clade V [27]. Other changes associated to relevant functions [27,30] 
such as H49Y in clade L (associated with monomer stability), A829T in clade S 
(fusion peptide), D936Y in clade GH [Heptad repeat 1 (HR1) associated with 
 
 











monomer stability], and P1263 in clade G (present in the cytoplasmic tail), were also 
detected in 1% to 3.4%.  
The evolutionary characterization of the wide spectrum of haplotypes contributes to 
determine the haplotype significance and its association with disease severity, 
response to antivirals, development of vaccines, and host genetic factors. 
The evolutionary rate of S protein estimated for all together clades was significantly 
higher than that previously reported by analyzing the entire genome [14,28]. This is 
expected since the complete genome includes several genomic regions with a high 
degree of conservation, while the S region is one of the most rapidly evolving in the 
SARS-CoV-2 genome [15]. Nonetheless, the spike evolution rate was quite similar to 
that obtained by analyzing this region during the first four months of the pandemic [15]. 
Although the evolutionary rate of all clades was similar, the founding clades (L, O, V, 
and S) showed evolutionary rates slightly lower than the most recent and currently 
more distributed ones (G, GH, and GR). This could be endorsed to the spread 
process in human populations since they are the most widely disseminated clades 
around the world. 
This study provides substantial data on the evolutionary process of S protein in the 
different clades of a virus that infects a susceptible population where a massive 
active immunization process has not yet been carried out. However, as it was 
aforementioned, the evolutionary rate of the S region remained stable throughout the 
nine considered months. In coming months, this scenario may modify and it would be 
necessary to re-evaluate the results from this study. In fact, a new clade named GV 
was described last months [32]. The inclusion in the study of only 2,100 of the 73,393 
available sequences on September 2020 is a limitation that implies a bias in the 
obtained results, although the sequence selection process was carefully carried out 
in order to generate a representative dataset from different time courses and a wide 
geographic range. 
Conclusions 
Since the S protein of SARS-CoV-2 mediates the entry in the host cell and is the 
target for most therapeutic candidates, it is essential to know the way this genomic 
region is evolving, given that changes in this protein could have consequences on 
viral transmission, response to antivirals, and efficacy of vaccines. On this basis, the 
results obtained in this work about the evolutionary rate of the spike protein during 
the first nine months of pandemic are very significant. Furthermore, the evolutionary 
study of each separate clade ads to the virus knowledge and deserves to be 
assessed in more detail since re-infection by a different phylogenetic clade has been 
reported. 
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Table 1. Number of SARS-CoV-2 sequences from GISAID database on September 
18th, by month and clade as per the selection criteria (Temporal structure). 
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Table 2. Summary of the haplotype and nucleotide diversity indices for the entire 
Spike and the Receptor Binding-Domain coding regions for each clade of SARS-
COV2. 
SPIKE   
Clade S H Hd Π 
G 100 86 0.704 ± 0.030 0.00037 ± 0.00003 
GH 102 89 0.704 ± 0.030 0.00038 ± 0.00003 
GR 112 89 0.683 ± 0.031 0.00038 ± 0.00003 
L 87 76 0.598 ± 0.035 0.00023 ± 0.00002 
O 81 68 0.793 ± 0.019  0.00040 ± 0.00002 
S 72 60 0.716 ± 0.027   0.00031 ± 0.00002 
 V 56 53 0.507 ± 0.036  0.00018 ± 0.00002 
General 134 107 0.857 ± 0.015 0.00052 ± 0.00003 
RBD   
Clade S H Hd Π 
G 15 15 0.183 ± 0.030 0.00028 ± 0.00005 
GH 17 19 0.196 ± 0.031 0.00032 ± 0.00006 
GR 23 23 0.281 ± 0.034 0.00041 ± 0.00006 
L 15 14 0.104 ± 0.024 0.00016 ± 0.00004 
O 9 9 0.193 ± 0.030 0.00027 ± 0.00004 
S 3 4 0.027 ± 0.013   0.00003 ± 0.00002 
V 3 4 0.020 ± 0.011 0.00003 ± 0.00001 
General 17 17 0.166 ± 0.029 0.00026 ± 0.00005 
 
 











S= Number of variable sites; H = Number of haplotypes; Hd = Haplotype diversity; π = 
Nucleotide diversity (per site) 
Table 3. Frequency of haplotypes with amino acid changes in the spike for each 
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N: Number, Hap= haplotype, aa= Amino acid, NC= No amino acid changes 
* Hap-1: S12, L18, R21, A222, N439, S477, T478, A522, E583, G614, Q675, E780, D936, 
V1068, and P1263. 
# Hap-252: L5, L8, H49, V367, A575, D614, A829, A846, D1084, and A1087. 
Table 4. Mean rates of the Spike-coding region (nt = 3822) for each clade of SARS-
COV2. 
Clade N Model Mean Rate HPD 95% inteval 
G 300 TIM2+f 1.47 x10-3 1.05 x10-3 - 1.95 x10-3 
GH 300 TIM2+f+I 1.42 x10-3 9.67 x10-4 - 1.94 x10-3 
GR 300 TIM2+f+I 1.69 x10-3 1.11 x10-3 - 2.30 x10-3 
L 300 TIM2+f 1.11 x10-3 5.90 x10-4 - 1.61 x10-3 
O 300 TIM2u+f 1.06 x10-3 7.20 x10-4 - 1.50 x10-3 
S 300 TN+F 1.33 x10-3 8.41 x10-4 - 1.83 x10-3 
V 300 HKY+F 1.15 x10-3 6.51 x10-4 - 1.64 x10-3 
General 300 GTR+F+I 1.08 x10-3 7.94 x10-4 - 1.41 x10-3 
 
 











N: Number of sequences 
FIGURES 
Figure 1 Median-joining haplotype networks. The seven clades of SARS-CoV 2 
described to date are compared to both the entire Spike and the RBD coding region. The 
diameters of the spheres are proportional to the frequency of haplotypes. The main 
















Figure 2 Test of temporal structure. Comparison of the evolutionary rates estimated 
for the original dataset vs. the date-randomized ones. This analysis was performed for the 
Spike-coding region (3822nt) of each clade. s.s.y = substitutions/site/year. 
 
 
